NRINX
Price
$29.53
Change
+$0.08 (+0.27%)
Updated
Jul 31 closing price
Net Assets
1.45B
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

NRINX vs VSCIX

NRINX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
NRINX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRINX is a Hold and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. NRINX (1.45B). VSCIX pays higher dividends than NRINX: VSCIX (1.23) vs NRINX (0.07). NRINX was incepted earlier than VSCIX: NRINX (8 years) vs VSCIX (29 years). NRINX (0.86) is less costly to investors than VSCIX (0.03). VSCIX is a more actively managed with annual turnover of: 17.00 vs. NRINX (12.00). NRINX has a lower initial minimum investment than VSCIX: NRINX (0) vs VSCIX (5000000). NRINX annual gain was more profitable for investors over the last year : 36.70 vs. VSCIX (22.58). VSCIX return over 5 years is better than : 35.13 vs. NRINX (23.87).
NRINXVSCIXNRINX / VSCIX
Total Expense Ratio0.860.032,867%
Annual Report Gross Expense Ratio0.860.032,867%
Fund Existence8 years29 years-
Gain YTD19.65214.591135%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.45B189B1%
Annual Yield % from dividends0.071.236%
Returns for 1 year36.7022.58163%
Returns for 3 years46.3143.44107%
Returns for 5 years23.8735.1368%
Returns for 10 yearsN/A156.07-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C